Used in the treatment of chronic graft-versus-host disease (cGVHD), this antibody targets the CSF1 receptor, blocking signaling by macrophage colony-stimulating factors. By inhibiting this pathway, it reduces the activation and survival of monocytes and macrophages, which play a key role in the inflammatory and fibrotic processes seen in cGVHD. It is particularly explored in patients who have not responded adequately to standard therapies, offering a targeted approach to modulate the immune response and improve clinical outcomes.